SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilead Science (GILD) Followers
GILD 124.90+0.2%Dec 29 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Meetmer who wrote (256)4/9/1997 3:35:00 AM
From: scaram(o)uche   of 961
 
Glaxo and BCHXF are clearly planning to submit for approval based on LFTs. Do you think they'll get it?

Thanks for your comments.......... makes you wonder about the viability of the drug combination concept that GILD was talking about. On the other hand, we have anti-HIV drugs being approved like crazy, and used in combinations, with no data regarding survival benefit (prior to approval).

Any feel for why GILD is talking declines in viral load rather than LFTs? Duration of the studies to date??

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News